Bristol-Myers Squibb Overview
- Founded
- 1887
- Status
- Public
- Employees
- 30,250
- Stock Symbol
- BMY
- Investments
- 70
- Share Price
- $65.46
- (As of Monday Closing)
Bristol-Myers Squibb General Information
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Stock Exchange
NYS
Primary Office
- 430 East 29th Street
- 14th Floor
- New York, NY 10016
- United States
Bristol-Myers Squibb Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $65.46 | $64.88 | $54.07 - $67.16 | $145B | 2.23B | 11.8M | -$2.76 |
Bristol-Myers Squibb Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 176,310,871 | 164,770,387 | 143,062,835 | 85,428,692 |
| Revenue | 42,810,000 | 42,518,000 | 26,145,000 | 22,561,000 |
| EBITDA | 7,945,000 | (4,855,100) | 6,186,300 | 6,854,000 |
| Net Income | (6,219,000) | (9,015,000) | 3,439,000 | 4,920,000 |
| Total Assets | 112,435,000 | 118,481,000 | 129,944,000 | 34,986,000 |
| Total Debt | 47,269,000 | 51,673,000 | 47,538,000 | 7,349,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bristol-Myers Squibb Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.
Request a free trialBristol-Myers Squibb Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncol
Drug Discovery
New York, NY
30,250
As of 2020
00000
000000000
00000
00000 &
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
000000000000000
Kenilworth, NJ
00000
As of 0000
00000000
00000
qua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commod
0000000000000
Thousand Oaks, CA
00000
As of 0000
00.000
000000000000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialBristol-Myers Squibb Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Kenilworth, NJ | 00000 | 00000000 | ||
| 00000 | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 00000000000 | 000.00 |
| 00000000 000000000 | Formerly VC-backed | Westlake Village, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Bristol-Myers Squibb Executive Team (53)
Bristol-Myers Squibb Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000 | Self | Board Member | 000 0000 |
| 000000 0000000 | Self | Board Member | 000 0000 |
| 000000 000000 00 | Self | Board Member | 000 0000 |
| 00000000 0000000 00 | Bristol-Myers Squibb | Chairman of the Board and Chief Executive Officer | 000 0000 |
| 00000 000000 00 | Self | Board Member | 000 0000 |
Bristol-Myers Squibb Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialBristol-Myers Squibb Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.
Request a free trialBristol-Myers Squibb Investments & Acquisitions (70)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 27-Apr-2021 | 00000 00000 00 | 00000 | Drug Discovery | |
| 00000 00000000 | 18-Mar-2021 | 00000 00000 00 | 0000 | Drug Delivery | |
| 0000000000 | 03-Mar-2021 | 00000 00000 00 | 00000 | Drug Discovery | |
| 0000000 0000000000 | 02-Mar-2021 | 00000 00000 00 | 0000 | Drug Discovery | |
| Orna Therapeutics | 24-Feb-2021 | Early Stage VC | 0000 | Biotechnology |
Bristol-Myers Squibb Subsidiaries (8)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| IFM Therapeutics | Drug Discovery | Boston, MA | 2015 |
| 000000000 | Drug Discovery | Brisbane, CA | 0000 |
| 0000000 | Biotechnology | Austin, TX | 0000 |
| 0000000 | Drug Discovery | Copenhagen North, Denmark | 0000 |
| 0000000 | Biotechnology | Summit, NJ | 0000 |
Bristol-Myers Squibb Exits (22)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 00000000 | 05-Jan-2021 | 00000 00000 00 | 00000 | Completed |
|
| 000000 00000000000 | 29-May-2020 | 000000000 | 0000 | Completed |
|
| 00000 00000000 | 18-Jan-2019 | 000000000 | 0000 | Completed |
|
| 000 000 | 19-Jul-2018 | 00000 00000 00 | 000.00 | Completed |
|
| Taris Biomedical (US) | 21-Dec-2017 | Later Stage VC | 0000 | Completed |
|